Suanfarma Suanfarma

X

Find Inavolisib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Inavolisib
Also known as: Gdc-0077, 2060571-02-8, Rg6114, Gdc0077, Ro7113755, Inavolisib [usan]
Molecular Formula
C18H19F2N5O4
Molecular Weight
407.4  g/mol
InChI Key
SGEUNORSOZVTOL-CABZTGNLSA-N
FDA UNII
L4C1UY2NYH

Inavolisib is an orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. inavolisib binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Dysregulation of the PI3K signaling pathway is frequently associated with tumorigenesis and tumor resistance to a variety of antineoplastic agents and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is frequently mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.
1 2D Structure

Inavolisib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
2.1.2 InChI
InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1
2.1.3 InChI Key
SGEUNORSOZVTOL-CABZTGNLSA-N
2.1.4 Canonical SMILES
CC(C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4C(COC4=O)C(F)F
2.1.5 Isomeric SMILES
C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F
2.2 Other Identifiers
2.2.1 UNII
L4C1UY2NYH
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (2s)-2-((2-((4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)propanamide

2. Gdc-0077

2.3.2 Depositor-Supplied Synonyms

1. Gdc-0077

2. 2060571-02-8

3. Rg6114

4. Gdc0077

5. Ro7113755

6. Inavolisib [usan]

7. L4c1uy2nyh

8. (2s)-2-[[2-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide

9. (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide

10. Rg-6114

11. Ro-7113755

12. N~2~-{(4s,11ap)-2-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}-l-alaninamide

13. Propanamide, 2-((2-((4s)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2s)-

14. Mfcd31382124

15. Sgeunorsozvtol-cabztgnlsa-n

16. X3n

17. Inavolisib [inn]

18. Unii-l4c1uy2nyh

19. Inavolisib [who-dd]

20. Gtpl9636

21. Chembl4650215

22. Schembl18360780

23. Bdbm295665

24. Amy16810

25. Ex-a2685

26. Nsc800729

27. S8668

28. Us10112932, Compound 101

29. Who 11204

30. Akos040741785

31. At36699

32. Cs-6459

33. Db15275

34. Gdc-0077; Rg6114

35. Nsc-800729

36. Ac-31594

37. Ms-26989

38. Hy-101562

39. A903455

40. Gdc-0077;rg6114;ro-7113755

41. (2s)-2-((2-((4s)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)propanamide

42. (2s)-2-({4-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-9-oxa-3,6-diazatricyclo[8.4.0.0,tetradeca-1(14),2,4,10,12-pentaen-12-yl}amino)propanamide

43. (s)-2-((2-((s)-4-(difluoromethyl)- 2-oxooxazolidin-3-yl)-5,6- Dihydrobenzo[f]imidazo[1,2- D][1,4]oxazepin-9- Yl)amino)propanamide

44. (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)propanamide (gdc-0077)

2.4 Create Date
2017-02-18
3 Chemical and Physical Properties
Molecular Weight 407.4 g/mol
Molecular Formula C18H19F2N5O4
XLogP31.5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count5
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area112
Heavy Atom Count29
Formal Charge0
Complexity641
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Phosphoinositide-3 Kinase Inhibitors

Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. (See all compounds classified as Phosphoinositide-3 Kinase Inhibitors.)


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY